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Laxative co-medication and changes in
defecation patterns during opioid use
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Monique Verduijn4, Pim Langendijk5, Marcel Bouvy1 and
Martina Teichert3,6
Abstract
Introduction: Opioid-induced constipation is a clinically relevant side effect and a cause of potentially avoidable drug-
related hospital admissions.
Objectives: To describe the presence of laxative co-medication, the reasons for not starting laxatives and to evaluate
changes in stool patterns of opioid initiators.
Methods: In this observational study community pharmacists evaluated the availability of laxative co-medication in
starting opioid users and registered reasons for non-use. Two opioid initiators per pharmacy were invited to complete
questionnaires (‘Bristol stool form scale’ and ‘Rome III Diagnostic Questionnaire for the Adult Functional
Gastrointestinal Disorders’) on their defecation prior to and during opioid use. Descriptive statistics and Chi square
tests were used to analyse reasons for non-use of laxatives and changes in defecation patterns.
Results: Eighty-one pharmacists collected data from 460 opioid initiators. Of those, 344 (74.8%) used laxatives con-
comitantly. Main reason not to use laxatives was that either prescribers or patients did not consider them necessary.
Sixty-seven (89.3%) of the 75 opioid starters with two questionnaires completed were not constipated at opioid start.
Eleven of them (16%) developed constipation during opioid use (Chi square p¼0.003). At follow-up within laxative users
10.6% were constipated compared to 20.7% in subjects without laxatives.
Conclusion: One in four opioid starters did not dispose of laxative co-medication, mainly because they were not
considered necessary by either the prescriber or the patient. The prevalence of constipation doubled during opioid use.
A watchful waiting strategy for the use of laxative co-medication might include a monitoring of defecation patterns with
validated questionnaires.
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Introduction
Opioids (e.g. morphine, oxycodone and fentanyl) are
effective analgesics, but may cause side effects, such as
drowsiness, nausea, decreased gastrointestinal (GI)
motility, increased GI transit time and subsequent con-
stipation.1,2 Opioid-induced constipation (OIC) has
been reported in approximately 90% of opioid
users,2–5 after even a single dose of morphine.2
According to the Rome III Diagnostic Criteria for
Functional Constipation, this condition includes a
number of symptoms, such as hard stools, infrequent
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stools (<3 per week), incomplete bowel evacuation or
unsuccessful defecation and the need for excessive
straining.6 Several risk factors to develop OIC have
been reported as more medical comorbidities or daily
medications, dehydration, co-medication reducing
bowel activity, physical abnormalities, decreased phys-
ical mobility, low fibre and fluid intake and reduced
privacy.1,3,7–9 Age might not be a factor, as a recent
study showed that within the first week after initiating
opioid therapy for chronic non-cancer pain, constipa-
tion occurred comparably in younger and older
patients with 32.8 and 35.9%, respectively.10
OIC was reported as an important cause of poten-
tially avoidable drug-related hospital admissions for
between 4.6 and 6.6% of all potentially preventable
drug-related hospital admissions.11–13 Moreover, OIC
has been associated with an increase in overall work
impairment.4 To avoid serious side effects and as treat-
ment of an already manifest OIC is more difficult, con-
comitant prophylactic use of laxatives is advised from
the start and throughout the duration of opioid treat-
ment.3,14–18 The practice of prescribing opioids without
concomitant laxatives as a prophylaxis and for symp-
tom control is regarded as inappropriate.1,14,19 From
laxatives available, osmotic agents (e.g. lactulose and
macrogol) are the preferred choice to prevent OIC.7,20
As OIC is preventable, healthcare providers should
take care of prophylaxis against constipation when
opioid therapy is prescribed. Consequently, prescribers
as well as pharmacists are expected to counsel patients
on symptoms and potential consequences of opioid side
effects and to advocate laxative use in combination with
opioids. Pharmacist-led interventions were shown to
increase the degree of laxative co-medication.21
Nevertheless, a cross sectional study in the United
States reported a monthly prevalence of concurrent
opioid and laxative use of only 55% in opioid users.1
This percentage equals the mean percentage of opioid
users with concomitant laxatives measured as a quality
indicator by national pharmacy dispensing data in the
Netherlands.22 Since the start of measurements in 2008
the score for laxative co-medication in opioid users
remained constantly low.22 This was in contrast to the
scores of other quality indicators such as the degree of
gastro-protection in susceptible users of non-steroidal
anti-inflammatory drugs, which improved to above
80% in the same period.22 Community pharmacists
gave a number of reasons for their low scores on this
quality indicator such as chronic diarrhoea which made
the use of laxatives superfluous. Or they explained their
low scores with laxatives from other sources than from
their community pharmacy dispensing the opioid.
According to a questionnaire among 211 GPs in the
Netherlands nearly half of them did not prescribe
a laxative because the patient refused their use.13
One-third of the GPs stated that the patients could
not take laxatives.13 However, this does not meet the
evidence and recommendations from literature.3 One-
fifth of the GPs answered that they would reconsider
laxatives later during the treatment, although all of
them were aware of the guideline recommendations to
start prophylaxis immediately.13 Information is lacking
whether patients were informed on opioid side effects
and the benefits of laxatives to take a well-informed
decision. Reasons not to use laxatives have not been
evaluated in community-dwelling patients at the start
of opioid treatment. Additionally, data on changes of
defecation patterns in community-dwelling patients
after opioid initiation are not available.
Therefore, this study evaluates the prevalence of
laxative co-medication at opioid treatment initiation
with reasons not to dispense or use laxatives and
assesses the change in defecation patterns of opioid ini-
tiators in relation with laxative co-medication.
Methods
Study design
This study is a prospective observational study on the use
of laxative co-medication in patients with a first opioid
dispensing of a community pharmacy in the Netherlands.
A first opioid dispensing was defined as no dispensing of
any opioid to a patient within the previous 12 months.
All 1981 community pharmacies in the Netherlands
were invited to participate in this study by means of the
weekly electronic newsletter of the Royal Dutch
Pharmacists Association and the website.
Additionally, during the national pharmacists’ congress
in October, pharmacists were personally invited by leaf-
lets and personal contact. The researchers also invited
pharmacists from their own network.
During the study period of in total two weeks, either
in November or in December 2016, participating com-
munity pharmacists checked the presence of a concomi-
tant laxative prescription for opioid initiators. If no
laxative was prescribed together with the opioid, the
availability of a laxative at home was questioned and
registered, otherwise laxative use was advised. Reasons
for not following this advice were noted. Two of these
patients per pharmacy were invited to fill questionnaires
on their defecation patterns prior and during opioid use.
Setting
In the Netherlands, pharmacists register all dispensed
medicines in their pharmacy information system.
Due to their legal and professional shared responsi-
bility for the safe and effective use of medication,23
pharmacists regularly contact prescribers when
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prescriptions may not be in accordance with prescrip-
tion. The majority of GPs and community pharmacists
regularly discusses prescribing guidelines in pharmaco-
therapy audit meetings.24
In the Netherlands, patients generally get their medi-
cation from one pharmacy.25 Moreover, patient medi-
cation records are exchanged between pharmacies if
patient’s consent was provided. Thus, community
pharmacists generally dispose of comprehensive files
on the medication of their patients. To support clinical
risk management, in 2015 an automated clinical rule
(CR) concerning the use of opioids without laxatives
was developed and implemented in the pharmacy infor-
mation systems. A decision tree within the CR provides
automated advice on relevant process steps and the
possibility to register the choices taken.
Ethical approval
The Medical Research Involving Human Subjects Act
did not apply to this study, according to the Medical
Research and Ethics Committee Nijmegen (‘2016-
2918’). The Institutional Review Board for practice
research of the University of Utrecht also evaluated
the study and granted approval (UPF1613).
Data collection
Degree of laxative co-medication and reasons not to dispense
or use it. Pharmacists were asked to collect information
on all first opioid dispensing for two weeks either
during November or the first two weeks of December
2016. These weeks were chosen at the beginning of the
internship of the first author and just before expected
extra work load before year’s end. According to
national dispensing data, on average three subjects
started opioids weekly per community pharmacy.
Consequently, on average six starters per pharmacy
were expected for the two weeks lasting study period.
For data collection, participating pharmacists received
a printed decision tree within the structure of the auto-
mated CR of the pharmacy medication surveillance
system (Figure 1). This decision tree is implemented in
the daily workflow of community pharmacies and known
to the pharmacy team. Beside the CR additional infor-
mation was collected on patients’ age, sex and the dis-
pensed opioid (chemical substance, dosage). If a laxative
was dispensed, information on the type of laxative and
dosage was registered. In case of no laxative dispensing,
pharmacists could register the reason for this by choosing
between a number of predefined options and with the
possibility to add other reasons.
Changes in constipation patterns after opioid
initiation. Starting opioid users of 18 years and older,
able to understand a questionnaire in Dutch and with
opioid use for at least three consecutive days, were
invited to complete questionnaires on their defecation
patterns. Pharmacists invited patients until two patients
per pharmacy were willing to consider participation,
following the sequence of offering a prescription in
the community pharmacy. Patients were provided
with oral and written information on the study, an
informed consent form and two paper questionnaires.
Participants had to complete two constipation ques-
tionnaires. The first one had to be completed before
the start of opioid treatment. The second one had to
be completed at the end of at least three days or after a
maximum of two weeks of subsequent opioid use.
Beside general patient information on age, sex and
the specific opioid initiated, the questionnaires were
composed of the ‘Bristol stool form scale’ and the
‘Rome III Diagnostic Questionnaire for the Adult
Functional GI Disorders’.6,26 The ‘Bristol stool form
scale’ is an instrument with images of stool types ran-
ging from the hardest (type 1) to the softest (type 7).
Type 1 and type 2 are described as hard stools (consti-
pation) and type 6 and 7 as abnormally loose stools
(diarrhoea). Type 3, 4 and 5 are considered as the
most normal stool forms.26 The ‘Rome III Diagnostic
Questionnaire for the Adult Functional GI Disorders’
comprises specific questions on aspects related to con-
stipation such as the frequency and composition of
defecation and the need to press.20
Constipation as the main outcome for the change in
defecation patterns was determined as being consti-
pated as well according to the criteria of the ‘Bristol
stool form scale’ as to the ‘Rome III Diagnostic
Questionnaire for the Adult Functional GI
Disorders’. This implied that a patient had to score
‘Type 1’ or ‘Type II’ in The Bristol stool forms scale
and at least two of the following criteria from the Rome
III questionnaire: (a) Straining during at least 25% of
defecations, (b) lumpy or hard stools in at least 25% of
defecations, (c) sensation of incomplete evacuation for
at least 25% of defecations, (d) sensation of anorectal
obstruction/blockage for at least 25% of defecations,
(e) manual manoeuvres to facilitate at least 25% of
defecations (e.g. digital evacuation, support of the
pelvic floor) and (f) fewer than three defecations per
week.6 As both questionnaires are validated on existing
tools, a pilot on their use was not necessary.
Data analysis
Degree of laxative co-medication and reasons not to use
laxatives. Descriptive statistics were used for patient
characteristics, opioid use and reasons for not dispen-
sing laxative co-medication. The proportion of opioid
users with laxative co-medication was calculated and
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stratified for different opioids, administration route and
prescribed daily dose (PDD) of the opioid dispensed.
Change in patient defecation patterns before and during opioid
use. Constipation was defined as being constipated
according to as well the Rome III criteria as the
Bristol stool form scale.6,26 Chi square tests were used
to test on changes in defecation patterns before and
after opioid initiation. Numbers and percentages of
patients with constipation at study start and during
follow-up were calculated, stratified by the use of laxa-
tives (yes/no).
Results
Pharmacists from 81 community pharmacies partici-
pated in this study (4% of the in total 1981 community
pharmacies in the Netherlands in 2016). They filled
decision trees for 460 opioid starters within total 538
opioid prescriptions (Table 1). The mean age of the 460
opioid initiators was 63 years, ranging from 16 to 102
years. Two hundred and fifty-eight (56%) individuals
were female. Most patients (99%) started with one
opioid, mainly oxycodone (73%).
Table 1 shows that 137 (30%) of the 460 patients
initiating opioids already disposed of a laxative, suffi-
cient to cover the period of opioid use. For 48 patients
(10%), the use of laxative medication was unknown
from pharmacy records, and thus patients used laxa-
tives from other sources than the community phar-
macy, that dispensed the opioid.
Of the remaining opioid starters, 207 (45.0%)
received a laxative concomitantly. In total 344
(74.8%) of the starting opioid users had a laxative
available as co-medication during their opioid use,
either due to laxatives already at home or due to a
new dispensing together with the opioid.
Consequently, one in four starting opioid users did
not dispose of a concomitant laxative during the first
period of opioid use. From these 116 subjects (25.2% of
all patients included) without a laxative, a total of 125
reasons not to use it were collected and shown in
Table 1. Main reasons to refuse laxatives were patients’
doubts on their necessity (44.1 %) or because of a
First opioid 
prescription
Sufficient laxative 
already available?
Laxative added?
No
Loperamide in use?
Opioid dispensed and
laxative already
available
Opioid dispensed
and loperamide
cessated
Opioid dispensed
and loperamide
continued
Advise for
loperamide
cessation during
opioid use
No
No
Advies to add laxative 
during opioid use
Yes
Opioid dispensed and
laxative started
Opioid dispensed and
no laxative added
 
Yes
Patient stops
loperamide
temporarily?
Yes
Yes
No
Figure 1. Decision tree to register laxative use in starting opioid users.
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waiting policy of patients on signs of OIC before start-
ing a laxative (32.4%). In 20.0% of the patients the
prescribers judged a laxative as not necessary because
of short term or on demand use. Co-medication with
loperamide was the first question in the CMR decision
tree as an indication for existing diarrhoea and a pos-
sible reason for no laxative dispensing. This was only
mentioned by one patient (0.2%). Detailed information
on laxative co-medication stratified for opioid sub-
stance, administration route and mean PDD of the
opioid is shown in supplement 1. Users of fixed com-
binations of different opioids and users of fentanyl tab-
lets or nasal spray, buprenorphine tablets or morphine
suppositories all disposed of laxative co-medication
(100%). However, the absolute user numbers were
small with 1–3 users per opioid formulation. Only the
Table 1. Characteristics of starting opioid users and reasons for refusing laxative co-medication.
Characteristics Frequencies
Patients with opioid prescriptions,a n 460
Age, mean (range) 63.2 (16–102)
Female, n (%) 258 (56.1)
Patients with one opioid, n (%) 453 (98.5)
Oxycodone 329 (72.6)
Fentanyl 69 (15.2)
Buprenorphine 26 (5.7)
Morphine 25 (5.5)
Tapentadol 4 (0.9)
Patients with two different opioids, n (%) 7 (1.5)
Oxycodone and morphine 2 (0.4)
Fentanyl and oxycodone 3 (0.7)
Fentanyl and morphine 1 (0.2)
Buprenorphine and fentanyl 1 (0.2)
Laxatives available to cover the period of opioid use, n (%) 137 (29.8)
Registered as current medication in pharmacy system 89 (19.3)
Not registered as current medication in pharmacy system 48 (10.4)
Insufficient number of laxatives available, n (%) 323 (70.2)
Laxative dispensed, n (%) 207 (45.0)
No laxative dispensed, n (%) 116 (25.2)b
Reasons not to use laxatives 25 (20.0)
Short-term opioid use or because of PRN medication
GP decided not to prescribe laxative co-medication immediately 11 (8.8)
Unnecessary because of low-dose opioids 6 (4.8)
Patient has (chronic) diarrhoea 5 (4.0)
Patient is unwilling to pay for laxative 5 (4.0)
Patient is going to use Over The Counter (OTC) medication 4 (3.2)
Inability to take laxative 1 (0.8)
Other reasons 68 (54.4)
Patient thinks laxative is not necessary 30 (44.1)
Patient is going to try without 22 (32.4)
Patient is in the terminal phase of life 6 (8.8)
Patient uses alternative products that stimulate bowel movements 3 (4.4)
Patient is under supervision of a nursing home that will determine the need for a laxative 3 (4.4)
Someone else picked up the medication for the patient 2 (2.9)
Laxative was dispensed elsewhere 1 (1.5)
Patient had intestinal inflammation 1 (1.5)
aHandling of co-dispensing laxatives in opioid initiators was registered by 81 community pharmacists.
bFor 116 opioid starters refusing laxative co-medication in total 143 reasons for refusal were recorded.
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users of higher dosages of morphine tablets (from
24mg) or oxycodone tablets (from 60mg) or fentanyl
transdermal patches (from 180 mcg) all used laxatives.
In users of lower dosages of these opioid preparations,
percentages of laxative co-medication were lower, being
lowest with 62.5% for users of morphine tablets
between 5 and 20mg. The lowest percentage was
detected in users for morphine drops with only half of
them using laxative co-medication.
Within the opioid initiators, 75 subjects of at least 18
years of age decided to participate in the study and
returned defecation questionnaires to their pharmacists
as well at opioid initiation as after follow-up. Their
average age was 56.8 years (range 20–87) and 48%
were female (Table 2). Eight starters were constipated
prior to opioid use. Sixty-seven (89.3%) subjects were
not constipated at opioid start from scores by as well
the ‘Bristol stool form scale’ as the ‘Rome III
Diagnostic Questionnaire for the Adult Functional GI
Disorders’ (Table 3). Eleven of them (16.4%) developed
constipation during opioid use. The Chi square test on
changes of defecation patterns before and during
opioid use was statistically significant (p¼0.003).
From the eight (10.7%) patients already being consti-
pated before opioid initiation, three (37.5%) were no
longer constipated during opioid use, all using laxatives
then. Sixteen (21.3%) subjects already used a laxative
before opioid initiation. Their number and percentage
increased to 47 (62.7%) during opioid use. At follow-up
from the 47 laxative users five (10.6%) were constipated
compared to six in the 29 opioid users (20.7%) without
laxative medication.
Discussion
Our study showed that one in four starting opioid users
did not dispose of a concomitant laxative during the
first period of opioid use. The corresponding percent-
age of 75% opioid users with concomitant laxative is
higher than the 55% reported by dispensing or
Table 2. Defecation patterns prior to opioid initiation and during opioid use.
Characteristics Frequencies
Patients answering questionnaires at start and during opioid usea, n 75
Age, mean (range) 56.8 (20–87)
Female, n (%) 36 (48.0)
Constipation prior to opioid use, n (%)
According to as well to ROME III and BSF criteria 8 (10.7)
According to ROME III criteria 20 (26.7)
According to BSF criteria 12 (16.0)
Constipation during opioid use, n (%)
According to as well ROME III and BSF criteria 16 (21.3)
According to ROME III criteria 38 (50.7)
According to BSF criteria 19 (25.3)
Use of laxative co-medication prior to opioid start, n (%)
Constipated patients due to
16 (21.3)
As well ROME III and BSF criteria 6 (37.5%)
ROME III criteria 10 (62.5%)
BSF criteria 7 (43.8%)
Use of laxative co-medication during opioid use, n (%)
Constipated patients due to
47 (62.7%)
As well ROME III and BSF criteria 10 (21.3%)
ROME III criteria 24 (51.1%)
BSF criteria 12 (25.5%)
Use of no laxative co-medication during opioid use, n (%)
Constipated patients due to
28 (37.3%)
As well ROME III and BSF criteria 6 (21.4%)
ROME III criteria 14 (50.0%)
BSF criteria 7 (25.0%)
aPatients were included by 50 community pharmacists.
bBSF: Bristol Stoel Form.
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prescription data only,1,22 but still seems too low to
meet the recommendations of current guidelines.
Registrations of participating pharmacists revealed
that 77% of the opioid starters without laxative co-
medication did not regard laxatives as necessary and
decided to start opioids without preventive co-
medication.
To meet the guidelines recommendations, there
seems to be room for the education of prescribers,
pharmacists and patients on opioid side effects.
However, our results also show that only 20.7% of
the opioid users without laxative actually developed
constipation. Thus, a watchful waiting strategy might
be an option provided that the stool patterns are regu-
larly monitored for constipation development. Both
prescribers as well as pharmacists have a professional
task in patient counselling to prevent OIC development
and related hospital admissions. In this the use of con-
stipation questionnaires might help patients to monitor
a deterioration of their defecation and signalize the
development of constipation. In our study, two vali-
dated constipation questionnaires, the ROME III and
the BSF criteria, were used to provide specific results
for OIC. Our results showed statistically significant
worsening of defecation patterns during opioid use
from 10.7% being constipated before opioid intake to
21.3% with constipation during opioid use.
The effectiveness of laxatives has already been shown
before by large studies.27–30 However, in our popula-
tion within laxative users during opioid use still 10.7%
were obstipated. This might be due to non-adherence to
laxatives or a suboptimal dosage of the laxative.
Some limitations have to be taken into account when
interpreting our study results. Only 4% of the commu-
nity pharmacies in the Netherlands participated.
Although available communication sources were used
intensely, no higher inclusion than 81 pharmacies could
be achieved. Participation was voluntary, and it is pos-
sible that participating pharmacists were more moti-
vated to prevent OIC and the percentage of laxative
co-medication reported here might be higher compared
to other pharmacies. Indeed, the percentage of starting
opioid users together with a laxative we found (75%)
was much higher than the 55% measured by the annual
national assessment of quality indicators from all com-
munity pharmacies in the Netherlands.22 Although
10% in difference were due to laxative availability not
covered from dispensing data, this could not fully
explain the higher scores of the pharmacists participat-
ing in this study. For the changes in defecation pat-
terns, 75 patients returned constipation questionnaires
before and during opioid use. The expectation to
include two patients per participating pharmacy was
not reached, and only 50 (62% from 81 participating)
community pharmacies managed to include patients for
answering the defecation questionnaires. Patient par-
ticipation was also voluntary. As patients had to be
able to read and understand the Dutch language,
patients with low health literacy were missed. This
group might be at a higher risk for opioid side effects
because they cannot afford laxative co-medication or
might have poor fibre intake. Thus, our findings
might underestimate the risk of OIC development
during opioid initiation. Additionally, terminally ill
patients were not reached by our study, and thus our
findings do not cover these patients. Furthermore, the
scores on the constipation scales were self-reported and
estimation might differ between patients. However,
constipation prior to and during opioid use was com-
pared on patient level, and a bias for changes during
opioid use seems to be limited.
A strength of our study was the high amount of CR
decision trees returned from participating pharmacies.
The 460 forms returned nearly met the expected num-
bers of six starters during a fortnight per pharmacy
(95%). As participating pharmacies came from all
over the Netherlands, we have no selection bias on
region or urbanity.
In conclusion one in four opioid starters did not
dispose of a concomitant laxative, mainly because
they were not considered necessary by patients. The
prevalence of constipation increased during opioid use
Table 3. Change in patients’ defecation patterns during opioid use.
Prior to opioid start
SumConstipated yes Constipated no
During opioid usea Constipated yes
(Laxativeb yes/no)
5 (62.5%) 11 (83.6%) 16
(5) (0) (5) (6)
Constipated no
(Laxative yes/no)
3 (37.5%) 56 (16.4%) 59
(3) (0) (34) (23)
Sum 8 (100%) 67 (100%) 75
aChi square test for changes in constipation patterns, p¼ 0.003.
bLaxative present during opioid use, either by dispensing of the community pharmacy dispensing the opioid either from other sources.
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and was higher in subjects without laxative co-medica-
tion. A watchful waiting strategy for the use of laxative
co-medication might include a monitoring of defecation
patterns with validated questionnaires.
Key notes
. One in four opioid starters did not dispose of a con-
comitant laxative.
. Main reasons were patients’ and prescribers’ doubts
on the necessity of a laxative and preference of a
waiting policy.
. The prevalence of constipation doubled during
opioid use.
. A delay for the start of laxative co-medication could
be justified by the monitoring of defecation patterns.
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